NF1 and neoplasm: Similar to tovorafenib, increased pERK levels were observed at lower concentrations and decreased pERK at higher concentrations with each type II RAF inhibitors in all three NF1-LOF tumor cell lines at the 1-hour timepoint (Fig. 4A–C).